SAN DIEGO– PhenoVista Biosciences, a provider of imaging-based, phenotypic assay services, announces Dr. Michelle Mack as their new Vice President of Business Development. Michelle has over 15 years of experience in the biopharmaceutical industry performing both scientific and business-related functions.
At PhenoVista, Michelle will develop and implement business plans for expanding the company’s drug-screening services into new regions, markets, and scientific fields. She will also lead the establishment of new partnerships and collaborations with cell and biotechnology companies to expand PhenoVista’s service offerings.
“I am thrilled to be joining PhenoVista at such a pivotal time in the company’s history, and eager to begin developing new collaborations and strategic partnerships that will enable the expansion of PhenoVista’s assay services into new therapeutic markets,” said Michelle Mack, Vice President of Business Development at PhenoVista. “I look forward to collaborating with PhenoVista’s talented scientific and commercial teams, to help solve customer needs, while accelerating the evolution and driving the growth of the organization.”
“We’re delighted to welcome Michelle to our growing team,” says James G. Evans, CEO and co-founder of PhenoVista. “Michelle brings a proven track record of building effective commercial teams in the demanding pre-clinical services space. It was especially important to us to bring in a leader with extensive experience at the bench; this is something for which Michelle is more than qualified, with over a decade in large pharma. Michelle’s addition to our team represents the beginning of an exciting, new phase of growth for PhenoVista.”
Previously, Michelle was the Vice President and General Manager of Data Commercialization at Champions Oncology, Inc. where she implemented commercial strategies for Champions’ data analytics technology platforms, led product development, and oversaw product initiatives.
Prior to her position at Champions, Michelle was the Senior Director of Business Development at Crown Bioscience, Inc. and a Senior Scientist of Antibody-drug Conjugate Biology at Pfizer. Michelle earned her Bachelor of Science in Biotechnology at Rochester Institute of Technology and her Master of Science in Microbiology and Doctor of Philosophy in Molecular Bioscience at Seton Hall University.
